PTT Public Company Limited will sell no more than two percent of Taiwan-based Lotus Pharmaceutical, reducing its current thirty-seven percent holding while retaining a stake of at least thirty-six percent, according to the company’s chief financial officer Pattaralada Sa-ngasang.

The transaction, scheduled to be completed by July two thousand twenty-six, is intended to increase financial flexibility for future investments in the life-sciences sector.

PTT owns the shares through its wholly owned subsidiary Innobic Asia, which will remain the major shareholder of Lotus Pharmaceutical following the divestment.

The company stated that the adjustment aligns its life-sciences strategy with evolving market conditions and competition, aiming to enable the pharmaceutical business to pursue self-funding growth while delivering long-term benefits to PTT and Thailand.

An investment analyst estimated that PTT will recognise a pre-tax special profit of approximately six point two to seven point six billion baht from the revaluation of its Lotus stake in the third quarter.

PTT is expected to continue receiving approximately one point eight billion baht in annual profit contributions from the business.

Lotus Pharmaceutical, listed on the Taiwan Stock Exchange, manufactures and distributes pharmaceutical products in markets including South Korea and the United States.

Innobic and Lotus share a stated goal of expanding the generic medicines business in Southeast Asia, with a focus on treatments for non-communicable diseases.

Innobic Asia chairman Buranin Rattanasombat previously noted that ageing populations across Asia are increasing demand for such treatments.